NOX 0.00% 9.9¢ noxopharm limited

"The number of metastatic lesions on initial presentation was 1...

  1. 4,947 Posts.
    lightbulb Created with Sketch. 790
    "The number of metastatic lesions on initial presentation was 1 in 13% of patients, 2–4 in 30%, and ≥5 in 40%" https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147191

    Seriously ill patient with only months to live, I would have thought would present the same numerical ratio of above. And that was my only point.

    Yet the two PR patients seem to be... "seem to be"... measured by PSA and pain scores not scans. As that is how the ann reads. Just confirm the PR is actually an abscpoal due to bone scans apart from the primary tumor as well and all is well. And as the study was changed to one only measurable tumor my scepticism is reasonable and the fact the ann states .... "In patients whose tumours are difficult to measure, clinical response is being determined on the basis of PSA levels and pain scores." And the patient 7 and 9 clearly do not state scans were involved my point stands.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
9.9¢
Change
0.000(0.00%)
Mkt cap ! $29.22M
Open High Low Value Volume
10.0¢ 10.5¢ 9.9¢ $4.773K 48.10K

Buyers (Bids)

No. Vol. Price($)
1 20574 9.9¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 38542 2
View Market Depth
Last trade - 16.10pm 29/11/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.